Source: yahoo_news
Source ID: yahoo:fe1cfe77c4bdf20e642c974714ca4f9c:VNDA
URL: https://finance.yahoo.com/healthcare/articles/vanda-pharmaceuticals-announces-positive-phase-224500905.html?.tsrc=rss
Symbol: (VNDA)
Published: 2026-09-29 18:45:00 EDT
Time precision: minute
Title: Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends to discuss these data with the U.S. Food and Drug Administration (FDA) and to submit a supplemental New Drug Application (sNDA) seeking approval of HETLIOZ® for DSWPD. If approved, HETLIOZ® would be the first FDA-approved medicine indicated for this condition.